Rani Therapeutics Holdings, Inc.

Gilson Michelle (Last) (First) (Middle) C/O RANI THERAPEUTICS LLC 2051 RINGWOOD AVE. (Street) SAN JOSE CALIFORNIA 95131 (City) (State) (Zip) UNITED STATES (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 08/01/2026 3. Issuer Name and Ticker or Trading Symbol Rani Therapeutics Holdings, Inc. [ RANI ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) (1) 10/30/2026 Class A Common Stock 12,500 $ 7.46 D Explanation of Responses: 1. The shares subject to the option are fully vested and exercisable. Remarks: Exhibit 24 - Power of Attorney /s/ Carlos Perez, Attorney-in-Fact 08/04/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 3: SEC 1473 (03-26) filed an initial statement of beneficial ownership (Form 3) as a Director of RANI, with an event date of 1473. The filer directly owns 12,500 shares of common stock. This is a routine insider-ownership disclosure with no indication of open-market purchases or activist intent.

RANI filed an 8-K (Item 5.02) reporting a director or officer change. not to u is involved in the change. The role noted: Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory . This is primarily an administrative disclosure; materiality depends on the seniority of the role and whether it reflects a strategic shift.

Rani Therapeutics (RANI) — Form 3 initial ownership for Nicholas Maestas (CFO) effective June 29, 2026. Maestas reports zero securities owned as of the filing date. Administrative — routine CFO initial-ownership disclosure; no shares, options, or RSUs held at filing.

Rani Therapeutics Holdings, Inc. (RANI) announced on June 29, 2026 the appointment of Nicholas M. Maestas (age 46) as Chief Financial Officer effective immediately, succeeding Svai Sanford who had announced his departure previously. Maestas brings biotech finance experience from Tempest Therapeutics (CFO, Jan 2025–Jun 2026), Alector (VP Finance & Strategy), and Immune Design (acquired by Merck in 2019). The departure from Tempest and appointment at RANI were unrelated to any disagreement. This is an orderly CFO transition with a credentialed biotech finance successor.

Rani Therapeutics Holdings held its 2026 Annual Meeting on May 28, 2026; as of the April 2, 2026 record date, approximately 123.8 million total shares (Class A and B combined) were outstanding. All seven director nominees — including Talat Imran, Mir Imran, Dennis Ausiello, Jean-Luc Butel, Vasudev Bailey, Abraham Bassan, and Lisa Rometty — were elected with strong support. Stockholders also ratified the appointment of CBIZ CPAs P.C. as independent auditor for FY2026. All proposals passed without material opposition, indicating stable governance.

Samsara Opportunity Fund, L.P. filed an amendment to its Schedule 13D for Rani Therapeutics Holdings, Inc. reporting beneficial ownership of 661,481 shares representing approximately 5.0% of the Class A common stock. This is an amendment providing updated position information as of the filing date. The 5% stake suggests Samsara remains an active shareholder monitoring Rani's progress in its oral biologic drug delivery platform.

Rani Therapeutics Holdings, Inc. offered shares of Class A common stock at $1.07 per share plus pre-funded warrants in lieu of shares (for purchasers near beneficial ownership limits) in a registered direct offering to institutional investors, pursuant to a securities purchase agreement. The total offering includes approximately 12.5 million shares and 6.2 million pre-funded warrant shares — roughly 18.7 million equivalent new shares at ~$1.07, for approximately $20 million gross proceeds. This is a meaningfully dilutive offering for a small-cap clinical-stage biotech, with use of proceeds likely funding pipeline advancement for the RaniPill oral biologic delivery system.

Rani Therapeutics Holdings, Inc. reported Q1 2026 financial results (quarter ended March 31, 2026) and provided a corporate update including a CFO leadership transition (Item 5.02). A Nasdaq listing compliance update (Item 3.01) was also disclosed. The press release is furnished as Exhibit 99.1. This multi-item filing covers Rani's quarterly results, a CFO change, and an ongoing Nasdaq compliance status — indicating the clinical-stage biotech is managing both operating progress and administrative governance challenges simultaneously.